Evaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2

NCT06997003 | Recruiting

• 1 other identifier: BL-LC04-TENOCT-6401
• Study Type: interventional
• Target: 81
• Locations: 1 country
• Sites: 1

Brief Summary

Prospective, post market clinical follow up study with a three months postoperative follow up to evaluate the visual and refractive outcomes of OCTAVIUS treatment when used as intended.

Conditions

Hyperopia and Myopia

Outcome Measures

Primary Outcomes (4)

• Percentage of eyes that achieve a Uncorrected Distance Visual Acuity of 20/40 or better

  Assessed for approximately 90 days

• Percentage of participants with binocular Uncorrected Distance Visual Acuity of 20/40 or better

  Assessed for approximately 90 days

• Percentage of eyes that achieve predictability (attempted versus achieved) of Manifest Refraction Spherical Equivalent (MRSE) within ± 0.50 D

  Assessed for approximately 90 days

• Percentage of eyes that achieve predictability (attempted versus achieved) of Manifest Refraction Spherical Equivalent (MRSE) within ± 1.00 D

  Assessed for approximately 90 days

Secondary Outcomes (4)

• Preservation of Corrected Distance Visual Acuity (CDVA)

  Assessed for approximately 90 days

• Preservation of Corrected Distance Visual Acuity (CDVA)

  Assessed for approximately 90 days

• Induced Manifest Refraction Astigmatism

  Assessed for approximately 90 days

• Incidence of Adverse Events

  Assessed from 0-90 days

Study Arms (3)

Hyperopic eyes and anterior treatment mode

EXPERIMENTAL

Device: Anterior treatment mode

Myopic eyes and anterior treatment mode

EXPERIMENTAL

Device: Anterior treatment mode

Myopic eyes and total treatment mode

EXPERIMENTAL

Device: Total treatment mode

Interventions

Anterior treatment mode DEVICE

Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment

Hyperopic eyes and anterior treatment mode

Total treatment mode DEVICE

Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment

Myopic eyes and total treatment mode

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects already scheduled for bilateral refractive laser surgery targeting emmetropia (attempted MRSE is between and including -0.50 D and +0.50 D).
• Minimum 18 years of age.
• Have read, understood, and signed an informed consent form (ICF).
• Have a stable refraction (i.e., a change of ≤ 0.50 D in sphere and cylinder) for both eyes as judged by the investigator.
• Have less than 0.75 D spherical equivalent (SE) difference between cycloplegic and manifest refractions at preoperative visit for both eyes.
• Study group 1 only: Have hyperopic refractive error with or without astigmatism; sphere between 0.00 D and 4.00 D, cylinder between 0.00 D and 3.00 D for both eyes; with a spherical equivalent (SE) between 0.50 D and 5.50 D for both eyes.
• Study groups 2 and 3 only: Have myopic refractive error with or without astigmatism; sphere between -8.00 D and 0.00 D, cylinder between 0.00 D and -4.00 D for both eyes; with a spherical equivalent (SE) between -10.00 D and -1.00 D for both eyes.
• Have CDVA of 20/25 (logMAR 0.1) or better in both eyes
• Have normal corneal topography as determined by the Investigator for both eyes.
• Have discontinued use of contact lenses for at least 2 weeks (for hard lenses) or 3 days (for soft lenses) prior to the pre-operative examination, and through the day of surgery.
• All contact lens wearers must demonstrate a stable refraction (within ± 0.50 D), as determined by MRSE, on two consecutive examinations at least 1 week apart, in both eyes and the axis of cylinder should not differ by more than 15 degrees from the baseline cycloplegic refraction for both eyes.
• Have the ability to lie flat without difficulty.
• Are willing and able to comply with the schedule for all post-surgery follow-up visits.

You may not qualify if:

• Subjects for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in less than 250 microns residual stroma thickness in any eye.
• Tear Break-Up time (TBUT) \<8 s in any eye.
• Mesopic pupil size larger than the optical zone of the planned treatment for any eye.
• History or evidence of active or inactive of corneal disease or infection in either eye (e.g., herpes simplex keratitis, herpes zoster keratitis, recurrent erosion syndrome, corneal dystrophy, etc.).
• Central corneal scars affecting visual acuity or unstable keratometry with irregular mires in any eye.
• Irregular astigmatism in any eye.
• Keratoconus or suspicion of keratoconus (sub-clinical, forme fruste), corneal dystrophy in any eye.
• Previous intraocular or corneal surgery in either eye that might confound the outcome of the study or increase the risk to the subject.
• Ocular muscle disorder including a strabismus or nystagmus, or other disorder affecting fixation in any eye.
• Evidence of retinal vascular disease in any eye.
• History or evidence glaucoma or glaucoma suspect in any eye.
• Acute or chronic disease or illness that would increase the operative risk, likely affect the wound healing or confound the outcomes of the study (e.g. immuno-compromised, connective tissue disease, clinically significant atopic disease, diabetes, etc.).
• Use chronic systemic medications that may confound the outcome of the study or increase the risk to the subject, including, but not limited to steroids, antimetabolites, etc.;
• Take medications contraindicated with LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone).
• Known sensitivity to medications used for standard LASIK treatment.

Sponsors & Collaborators

• Bausch & Lomb GmbH: lead

Study Sites (1)

Site 01

Zlín, Czech Republic, 76001, Czechia

RECRUITING

MeSH Terms

Conditions

Hyperopia; Myopia

Condition Hierarchy (Ancestors)

Refractive Errors; Eye Diseases

Study Officials

• Natasa Orlic-Pleyer

  Bausch & Lomb GmbH

  STUDY DIRECTOR

Central Study Contacts

Daniel Sagan

CONTACT

+49 1726927757; daniel.sagan@bausch.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 21, 2025
• First Posted: May 30, 2025
• Study Start: June 16, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: June 22, 2025

Record last verified: 2025-06

Locations

CZ (1)